Myeloproliferative Neoplasms (MPN)

Dr. Cutler received his MD from McGill University, Montreal, Canada. He subsequently received his MPH from the Harvard school of Public Health. He completed postgraduate training in Internal Medicine at Royal Victoria Hospital, Montreal, followed by a fellowship in Hematology/Oncology at DFCI. In 2002, he joined DFCI, where he currently is a member of the Hematologic Malignancies staff.

Dr. M. Sitki Copur is a nationally known medical oncologist. He is an adjunct faculty professor at the University of Nebraska Medical Center Department of Internal Medicine Division of Hematology/Oncology. He graduated from medical school at Hacettepe University in Ankara, Turkey. He served an Internal Medicine Residency, also in Turkey, before completing an internship and residency, both at Chicago Medical School in Chicago. His medical oncology fellowship was at the National Cancer Institute in Bethesda, Maryland. He is board certified in Internal Medicine and Medical Oncology, and serves on

Ehab Atallah, MD, is a Professor of Medicine and Section Head of hematological malignancies in the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital. He graduated from Cairo University School of Medicine in 1994, then completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as Chief Fellow. He then went on to complete a leukemia fellowship at M.D. Anderson Cancer Center

Dr. Erba entered medical school for the sole purpose of learning more about human diseases, so that he could focus his laboratory efforts on improving the human condition. However, he was surprised to find himself drawn to clinical care. He cares for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, Dr. Erba has had the privilege of treating people facing life-threatening illnesses. He strives to gain the trust of each of his patients, so that he can help them make difficult treatment decisions. He engages in clinical research

Dr. Abel received his MD and MPH from Columbia University in 2000. He completed his postgraduate training in internal medicine at Massachusetts General Hospital and his hematology/oncology fellowship at Dana-Farber Cancer Institute. In 2007, he joined Dana-Farber and is a member of the Hematologic Malignancies staff, as well as the Center for Outcomes and Policy Research.

Dr. Abdel-Wahab is a hematologist/oncologist who specializes in the research and treatment of patients with a variety of myeloid malignancies, which include myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.